Michael J. Krowka

Michael J. Krowka

Auto-generated profile, based on publicly available information

Michael J. Krowka

Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Chest
Verified
Journal Article
Closed access
MKMichael J. Krowka
Michael J. Krowka
DMDave P. Miller
Dave P. Miller
RBRobyn J. Barst
Robyn J. Barst
DTDarren Taichman
Darren Taichman
RDRaed A. Dweik
Raed A. Dweik
MMMichael D. McGoon
Michael D. McGoon

1 February 2008 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Open access
PDF file
KSKaren L. Swanson
Karen L. Swanson
MKMichael J. Krowka
Michael J. Krowka
Pulmonary artery hypertension may develop in some patients with liver disease and portal hypertension. Although pulmonary artery hypertension may be asymptomatic in its early stages, it should be looked for especially if a patient is a candidate for liver transplantation, as it may make transplantation riskier.

16 June 2015 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
LFLynn A. Fussner
Lynn A. Fussner
VIVivek N. Iyer
Vivek N. Iyer
RCRodrigo Cartin‐Ceba
Rodrigo Cartin‐Ceba
GLGrace Lin
Grace Lin
KWKymberly D. Watt
Kymberly D. Watt
MKMichael J. Krowka
Michael J. Krowka
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are pulmonary vascular complications of portal hypertension with divergent clinicopathologic features and management. The presence of intrapulmonary vascular dilatations (IPVDs), detected by agitated saline contrast‐enhanced transthoracic echocardiography (cTTE), is an essential feature of HPS but is not typically characteristic of POPH. Although IPVDs have been reported rarely in POPH, the prevalence and significance of this finding have not been systematically studied. We conducted a retrospective chart review of 80 consecutive patients diagnosed with POPH from January 1, 2002 to June 30, 2014 with documentation of cTTE findings, pulmonary hemodynamics, oxygenation, and survival. A total of 34 of the 80 patients (42%) underwent cTTE during initial diagnosis of POPH. IPVDs were detected in 20/34 patients (59%); intracardiac shunting was detected in 9/34 patients (26%; 4 also had IPVDs); and 9 patients (26%) had negative cTTE with no evidence of IPVD or intracardiac shunting. Patients with IPVD had decreased survival as compared to those without IPVD (P = 0.003), a trend that persisted after exclusion of liver transplant recipients (P =  0.07). The IPVD group had a trend toward higher Model for End‐Stage Liver Disease score with and without incorporating sodium (MELD or MELD‐Na; P = 0.05 for both). The right ventricular index of myocardial performance (RIMP) was lower in the IPVD group (median, 0.4 versus 0.6; P = 0.006). Patients with moderate or large IPVDs (n = 6) had worse oxygenation parameters (partial pressure of arterial oxygen, diffusing capacity of the lung for carbon monoxide, and alveolar‐arterial oxygen gradient) as compared to the rest of the cohort. Unexpectedly, IPVDs were frequently documented in POPH and associated with decreased survival. To further understand this observation, we recommend screening for IVPD in all patients with POPH. Liver Transpl 21:1355‐1364, 2015. © 2015 AASLD.


18 March 2025 in Liver Transplantation
Verified
Journal Article
Open access
HDHilary M. DuBrock
Hilary M. DuBrock
LSLaurent SAVALE
Laurent SAVALE
OSOlivier Sitbon
Olivier Sitbon
SRSarah Raevens
Sarah Raevens
SKSteven M. Kawut
Steven M. Kawut
MKMichael J. Krowka
Michael J. Krowka
Portopulmonary hypertension (POPH), pulmonary artery hypertension (PAH) that develops in the setting of portal hypertension, has long been of significant interest to the pulmonary, cardiology and hepatology communities. Optimal management of POPH has been challenging to define due to lack of evidence from clinical trials regarding PAH therapies and uncertainty regarding the role of liver transplantation (LT). Initially, the high risk of intraoperative and early post-transplant death in predominantly untreated patients with POPH tempered consideration of LT. More recently, the observation that POPH can improve, and sometimes even resolve, following LT, has led to reconsideration of the role of LT in selected patients. The first International Liver Transplantation Society (ILTS) POPH and hepatopulmonary syndrome practice guideline was a multidisciplinary consensus of expert opinions based on available evidence. Since that publication, hemodynamic definitions, management approaches and POPH Model for End Stage Liver Disease exception criteria have evolved and there have been new randomized controlled trials in POPH as well as studies regarding long-term outcomes. In order to ensure the guidelines remained current and reflected recent evidence, the original writing committee of the 2016 guidelines, leaders of the ILTS Cardiovascular Special Interest Group and colleagues active in POPH research were invited to participate in the writing committee. In this document, approved for publication by the ILTS executive council, we provide an update to the prior guidelines with expert recommendations to guide and advance POPH management. Recommendations in these guidelines are based on expert opinion and available evidence and were agreed upon by consensus. Export

1 September 2016 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
WBWaleed Brinjikji
Waleed Brinjikji
CWChristopher P. Wood
Christopher P. Wood
GLGiuseppe Lanzino
Giuseppe Lanzino
HCHarry J. Cloft
Harry J. Cloft
SMSanjay Misra
Sanjay Misra
VIVivek Iyer
Vivek Iyer
Rationale: There is sparse published literature on the causes and outcomes of hospitalization of patients with hereditary hemorrhagic telangiectasia (HHT). Objectives: To evaluate rates of various complications, comorbidities, and in-hospital outcomes of patients with HHT using a large, multihospital inpatient database. Methods: We identified patients with HHT in the U.S. Nationwide Inpatient Sample between 2000 and 2012. Rates of hemorrhagic, neurological, hepatic, and cardiopulmonary complications among hospitalized patients with HHT were evaluated. We also studied procedure use rates for blood transfusion, endoscopy, and epistaxis treatment. Hospitalization outcomes, including in-hospital mortality, discharge status, charges, and length of stay, were evaluated. Measurements and Main Results: We identified 10,293 patients with HHT. The mean age of the HHT population was 60.7 years. Sixty percent of patients were female. More than 75% of HHT hospitalizations occurred in those older than 50 years of age. Patients with HHT had high rates of bleeding-related complications, including anemia (53.3%), epistaxis (16.2%), and gastrointestinal bleeding (10.8%). Overall, bleeding complications accounted for 62.7% of HHT-related complications. Thirty-eight percent of hospitalized patients with HHT received one or more transfusions of a blood product. Cardiopulmonary complications were present in 41.0% of the cases. Congestive heart failure was the second most common individual complication among patients with HHT, affecting 19.9% of patients. The in-hospital mortality rate was 1.9%. Conclusions: In this large, nationwide study, we found that nearly two-thirds of patients hospitalized with HHT experienced a bleeding-related complication. Nearly 40% of hospitalized patients with HHT required transfusion of blood products. Cardiopulmonary complications, including congestive heart failure, were the second most common complication. The high burden of bleeding-related complications points to a significant unmet clinical need for these patients.